DAFTAR PUSTAKA

Arora, N., Talhouk, A., McAlpine, J. N., Law, M. R., & Hanley, G. E. (2018). Long-term mortality among women with epithelial ovarian Carcinoma: A population-based study in British Columbia, Canada. *BMC Carcinoma*, *18*(1), 1039. https://doi.org/10.1186/s12885-018-4970-9

Arora, T., Mullangi, S., & Lekkala, M. R. (2022). Ovarian Carcinoma. *StatPearls [Internet]*.

Aziz, S. A., Nelwan, E. J., Sukrisman, L., & Suhendro, S. (2018). Higher cut-off serum procalcitonin level for sepsis diagnosis in metastatic solid tumor patients. *BMC Research Notes*, *11*(1), 84. https://doi.org/10.1186/s13104-018-3204-1

Bizoń, M., Awiżeń-Panufnik, Z., & Sawicki, W. (2023). Comparison of Interleukin-6 with Other Markers in Diagnosis of Ovarian Carcinoma. *Journal of Personalized Medicine*, *13*(6), 980.

Braicu, Buse, Busuioc, Drula, Gulei, Raduly, Rusu, Irimie, Atanasov, Slaby, Ionescu, & Berindan-Neagoe. (2019). A Comprehensive Review on MAPK: A Promising Therapeutic Target in Carcinoma. *Carcinomas*, *11*(10), 1618. https://doi.org/10.3390/Carcinomas11101618

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global Carcinoma statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 Carcinomas in 185 countries. *CA: A Carcinoma Journal for Clinicians*, *68*(6), 394–424. https://doi.org/10.3322/caac.21492

Brett M., R., Jennifer B., P., Thomas A., S., Brett M., R., Jennifer B., P., & Thomas A., S. (2017). Epidemiology of ovarian Carcinoma: A review. *Carcinoma Biology & Medicine*, *14*(1), 9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084

Browning, L., Patel, M. R., Horvath, E. B., Tawara, K., & Jorcyk, C. L. (2018). IL-6 and ovarian Carcinoma: Inflammatory cytokines in promotion of metastasis. *Carcinoma Management and Research*, *10*, 6685.

Bulun, S. E., Wan, Y., & Matei, D. (2019). Epithelial mutations in endometriosis: Link to ovarian Carcinoma. *Endocrinology*, *160*(3), 626–638.

Campos, C., Sarian, L. O., Jales, R. M., Hartman, C., Araújo, K. G., Pitta, D., Yoshida, A., Andrade, L., & Derchain, S. (2016). *Performance of the Risk of Malignancy Index for Discriminating Malignant Tumors in Women With Adnexal Masses*. 143–152. https://doi.org/10.7863/ultra.15.01068

Canat, L., Atalay, H. A., Can, O., Alkan, İ., & Ötünçtemur, A. (2018). Serum procalcitonin levels in prostate Carcinoma: A new biomarker? *Urologia Journal*, *85*(2), 46–50.

Chang, L., Guo, R., & Yuan, Z. (2017). IL-36α suppresses proliferation of ovarian Carcinoma cells. *Tumor Biology*, *39*(6), 101042831770691. https://doi.org/10.1177/1010428317706918

Clel . (2021). Procalcitonin. In *StatPearls [Internet]*. StatPearls Publishing.

Dala S., Sharma, A., Kumar, L., Sharma, J. B., Roy, K. K., Singh, N., & Vanamail, er potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian *Clinica Chimica Acta*, *482*, 27–32.

Del Giudice, M., & Gangestad, S. W. (2018). Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. *Brain, Behavior, and Immunity*, *70*, 61–75. https://doi.org/10.1016/j.bbi.2018.02.013

Deng, K., Yang, C., Tan, Q., Song, W., Lu, M., Zhao, W., Lou, G., Li, Z., Li, K., & Hou, Y. (2018). Sites of distant metastases and overall survival in ovarian Carcinoma: A study of 1481 patients. *Gynecologic Oncology*, *150*(3), 460–465.

Dharmajaya, R., & Sari, D. K. (2021). Role and value of inflammatory markers in brain tumors: A case controlled study. *Annals of Medicine and Surgery*, *63*, 102107. https://doi.org/10.1016/j.amsu.2021.01.055

Dou, Y., Jiang, X., Xie, H., He, J., & Xiao, S. (2019). The Jun N-terminal kinases signaling pathway plays a “seesaw” role in ovarian carcinoma: A molecular aspect. *Journal of Ovarian Research*, *12*(1), 99. https://doi.org/10.1186/s13048-019-0573-6

El Haddad, H., Chaftari, A.-M., Hachem, R., Chaftari, P., & Raad, I. I. (2018). Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Carcinoma. *Clinical Infectious Diseases*, *67*(6), 971–977. https://doi.org/10.1093/cid/ciy331

Fu, Z., Brooks, M. M., Irvin, S., Jordan, S., Aben, K. K., Anton-Culver, H., Bandera, E. V., Beckmann, M. W., Berchuck, A., & Brooks-Wilson, A. (2023). Lifetime ovulatory years and risk of epithelial ovarian Carcinoma: A multinational pooled analysis. *JNCI: Journal of the National Carcinoma Institute*, *115*(5), 539–551.

Gaitskell, K., Green, J., Pirie, K., Barnes, I., Hermon, C., Reeves, G. K., & Beral, V. (2018). Histological subtypes of ovarian Carcinoma associated with parity and breastfeeding in the prospective Million Women Study. *Carcinoma Epidemiology*.

Ghoneum, A., Afify, H., Salih, Z., Kelly, M., & Said, N. (2018). Role of tumor microenvironment in ovarian Carcinoma pathobiology. *Oncotarget*, *9*(32), 22832–22849. https://doi.org/10.18632/oncotarget.25126

Grill, S., Hamann, M., Hartmann, O., Hederich, P., & Klein, E. (2020). Early Detection of ovarian Carcinoma—An enduring challenge: Pro-neurotensin and procalcitonin as promising biomarkers. *J Mol Biomark Diagn*, *11*(422), 2.

Gupta, K. K., Gupta, V. K., & Naumann, R. W. (2019). Ovarian Carcinoma: Screening and future directions. *International Journal of Gynecologic Carcinoma*, *29*(1).

Hagemann, T., Robinson, S. C., Thompson, R. G., Charles, K., Kulbe, H., & Balkwill, F. R. (2007). Ovarian Carcinoma cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. *Molecular Carcinoma Therapeutics*, *6*(7), 1993–2002. 158/1535-7163.MCT-07-0118

Harı & Stack, M. S. (2018). *With Great Age Comes Great Metastatic Ability: and the Appeal of the Aging Peritoneal Microenvironment*.

Harı ıta, C. M. (2019). NF-κB Signaling in Ovarian Carcinoma. *Carcinomas*, *11*(8), g/10.3390/Carcinomas11081182

He, X., Chen, L., Chen, H., Feng, Y., Zhu, B., & Yang, C. (2021). Diagnostic accuracy of procalcitonin for bacterial infection in liver failure: A meta-analysis. *Bioinorganic Chemistry and Applications*, *2021*.

Henderson, J. T., Webber, E. M., & Sawaya, G. F. (2018a). Screening for Ovarian Carcinoma: An Updated Evidence Review for the U.S. Preventive Services Task Force. In *Screening for Ovarian Carcinoma: An Updated Evidence Review for the U.S. Preventive Services Task Force [Internet]*. Agency for Healthcare Research and Quality (US). https://www.ncbi.nlm.nih.gov/books/NBK493401/

Henderson, J. T., Webber, E. M., & Sawaya, G. F. (2018b). Screening for Ovarian Carcinoma: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*, *319*(6), 595. https://doi.org/10.1001/jama.2017.21421

Huang, Y., Hu, C., Ye, H., Luo, R., Fu, X., Li, X., Huang, J., Chen, W., & Zheng, Y. (2019). Inflamm-aging: A new mechanism affecting premature ovarian insufficiency. *Journal of Immunology Research*, *2019*.

Iversen, L., Fielding, S., Lidegaard, Ø., & Hannaford, P. C. (2021). Contemporary hormonal contraception and cervical Carcinoma in women of reproductive age. *International Journal of Carcinoma*, *149*(4), 769–777. https://doi.org/10.1002/ijc.33585

Jia, D., Nagaoka, Y., Katsumata, M., & Orsulic, S. (2018). Inflammation is a key contributor to ovarian Carcinoma cell seeding. *Scientific Reports*, *8*(1), 12394. https://doi.org/10.1038/s41598-018-30261-8

Jungen, M. J., ter Meulen, B. C., van Osch, T., Weinstein, H. C., & Ostelo, R. W. J. G. (2019). Inflammatory biomarkers in patients with sciatica: A systematic review. *BMC Musculoskeletal Disorders*, *20*(1), 156. https://doi.org/10.1186/s12891-019-2541-0

Kajikawa, S., Ohashi, W., Kato, Y., Fukami, M., Yonezawa, T., Sato, M., Kosaka, K., Kato, T., Tanaka, H., & Ito, S. (2021). Prognostic impact of serum procalcitonin in non-small cell lung Carcinoma. *Tumori Journal*, *107*(5), 385–391.

Khalafi-Nezhad, A., Ebrahimi, V., Ahmadpour, F., Momtahan, M., Robati, M., Saraf, Z., Ramzi, M., Jowkar, Z., & Ghaffari, P. (2020). Parity as a prognostic factor in patients with advanced-stage epithelial ovarian Carcinoma. *Carcinoma Management and Research*, 1447–1456.

Koushik, A., Grundy, A., Abrahamowicz, M., Arseneau, J., Gilbert, L., Gotlieb, W. H., Lacaille, J., Mes-Masson, A.-M., Parent, M.-É., & Provencher, D. M. (2017). Hormonal and reproductive factors and the risk of ovarian Carcinoma. *Carcinoma Causes & Control*, *28*(5), 393–403.

Kroeger Jr, P. T., & Drapkin, R. (2017). Pathogenesis and heterogeneity of ovarian Carcinoma. *Current Opinion in Obstetrics & Gynecology*, *29*(1), 26.

La [illegible]rian Carcinoma: Epidemiology and risk factors. *European Journal of* [illegible]*on*, *26*(1), 55–62.

Leu[illegible]tycki, J., Guénel, P., & Koushik, A. (2023). Occupational environment and [illegible]isk. *Occupational and Environmental Medicine*, *80*(9), 489–497.

Li, J[illegible]H., & Guo, R. (2017). C-reactive protein and risk of ovarian Carcinoma: A [illegible]nd meta-analysis. *Medicine*, *96*(34).

Li, Y., Zhong, X., Cheng, G., Zhao, C., Zhang, L., Hong, Y., Wan, Q., He, R., & Wang, Z. (2017). Hs-CRP and all-cause, cardiovascular, and Carcinoma mortality risk: A meta-analysis. *Atherosclerosis*, *259*, 75–82.

Liu, Z., Jin, K., Guo, M., Long, J., Liu, L., Liu, C., Xu, J., Ni, Q., Luo, G., & Yu, X. (2017). Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic Carcinoma. *Annals of Surgical Oncology*, *24*(2), 561–568.

Memar, M. Y., Varshochi, M., Shokouhi, B., Asgharzadeh, M., & Kafil, H. S. (2017). Procalcitonin: The marker of pediatric bacterial infection. *Biomedicine & Pharmacotherapy*, *96*, 936–943.

Miyake, T., Iida, H., Shimizu, T., Ueki, T., Kojima, M., Ohta, H., Yamaguchi, T., Kaida, S., Mekata, E., & Endo, Y. (2021). The elevation in preoperative procalcitonin is associated with a poor prognosis for patients undergoing resection for colorectal Carcinoma. *Digestive Surgery*, *38*(1), 80–86.

Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019). Ovarian Carcinoma in the world: Epidemiology and risk factors. *International Journal of Women's Health*, *11*, 287.

Munn, L. L. (2017). Carcinoma and inflammation. *WIREs Systems Biology and Medicine*, *9*(2). https://doi.org/10.1002/wsbm.1370

Muqaku, B., Pils, D., Mader, J. C., Aust, S., Mangold, A., Muqaku, L., Slany, A., Del Favero, G., & Gerner, C. (2020). Neutrophil Extracellular Trap Formation Correlates with Favorable Overall Survival in High Grade Ovarian Carcinoma. *Carcinomas*, *12*(2), 505. https://doi.org/10.3390/Carcinomas12020505

Nardone, V., Giannicola, R., Bianco, G., Giannarelli, D., Tini, P., Pastina, P., Falzea, A. C., Macheda, S., Caraglia, M., Luce, A., Zappavigna, S., Mutti, L., Pirtoli, L., Giordano, A., & Correale, P. (2021). Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Carcinoma Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. *Frontiers in Oncology*, *11*, 684110. https://doi.org/10.3389/fonc.2021.684110

Nehring, S. M., & Patel, B. C. (2017). *C reactive protein (CRP)*.

Orr, B., & Edwards, R. P. (2018). Diagnosis and treatment of ovarian Carcinoma. *Hematology/Oncology Clinics*, *32*(6), 943–964.

Peres, L. C., Mallen, A. R., Townsend, M. K., Poole, E. M., Trabert, B., Allen, N. E., Arslan, A. A., Dossus, L., Fortner, R. T., & Gram, I. T. (2019). High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Carcinoma: Results from the Ovarian Carcinoma Cohort ConsortiumC-Reactive Protein and Ovarian Carcinoma Risk. *Carcinoma Research*, *79*(20), 5442–5451.

Quadir, A. F., & Britton, P. N. (2018). Procalcitonin and C-reactive protein as biomarkers for neonatal

ournal of Paediatrics and Child Health, *54*(6), 695–699.

Ran ., & Barua, A. (2023). Age-associated molecular changes may predispose ıant transformation leading to ovarian Carcinoma (OVCA). *Carcinoma* ıplement_1), A015–A015. https://doi.org/10.1158/1538-7445.AGCA22-

Rasmussen, L. J. H., Moffitt, T. E., Eugen-Olsen, J., Belsky, D. W., Danese, A., Harrington, H., Houts, R. M., Poulton, R., Sugden, K., Williams, B., & Caspi, A. (2019). Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood. *Journal of Child Psychology and Psychiatry*, *60*(2), 199–208. https://doi.org/10.1111/jcpp.12928

Ruth, K. S., Day, F. R., Hussain, J., Martínez-Marchal, A., Aiken, C. E., Azad, A., Thompson, D. J., Knoblochova, L., Abe, H., & Tarry-Adkins, J. L. (2021). Genetic insights into biological mechanisms governing human ovarian ageing. *Nature*, *596*(7872), 393–397.

Saed, G. M., Diamond, M. P., & Fletcher, N. M. (2017). Updates of the role of oxidative stress in the pathogenesis of ovarian Carcinoma. *Gynecologic Oncology*, *145*(3), 595–602.

Sánchez-Iglesias, J. L., Morales-Coma, C., Minig, L., Lago, V., Domingo, S., Mancebo, G., Siegrist, J., Fidalgo García, M. S., Llueca, A., & Serra, A. (2024). Procalcitonin and C-reactive protein as early markers of anastomotic leakage in intestinal resections for advanced ovarian Carcinoma (EDMOCS). *Acta Obstetricia et Gynecologica Scandinavica*.

Savant, S. S., Sriramkumar, S., & O'Hagan, H. M. (2018). The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian Carcinoma. *Carcinomas*, *10*(8), 251.

Savitri, I., & Askandar, B. (2021). The Role of Procalcitonin as a Prognostic Variable in Ovarian Carcinoma Patients at Dr. Soetomo General Hospital Surabaya. *Indonesian Journal of Carcinoma*, *15*(3), 107–111.

Schüler-Toprak, S., Weber, F., Skrzypczak, M., Ortmann, O., & Treeck, O. (2018). Estrogen receptor β is associated with expression of Carcinoma associated genes and survival in ovarian Carcinoma. *BMC Carcinoma*, *18*(1), 981. https://doi.org/10.1186/s12885-018-4898-0

Shrotriya, S., Walsh, D., Nowacki, A. S., Lorton, C., Aktas, A., Hullihen, B., Benanni-Baiti, N., Hauser, K., Ayvaz, S., & Estfan, B. (2018). Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. *PLOS ONE*, *13*(8), e0202555. https://doi.org/10.1371/journal.pone.0202555

Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Carcinoma statistics, 2020. *CA: A Carcinoma Journal for Clinicians*, *70*(1), 7–30. https://doi.org/10.3322/caac.21590

Singh, N., Baby, D., Rajguru, J. P., Patil, P. B., Thakkannavar, S. S., & Pujari, V. B. (2019). Inflammation and Carcinoma. *Annals of African Medicine*, *18*(3), 121–126. https://doi.org/10.4103/aam.aam_56_18

Sköld, C., Tolf, A., Corvigno, S., Dahlstrand, H., Stålberg, K., Enblad, G., Sundström Poromaa, I., Mezheyeuski, A., Glimelius, I., & Koliadi, A. (2021). *Association between parity, histopathological tumor features and survival in high-grade serous ovarian Carcinoma*.

Stev ckwood, S. (2019). *Ovarian Carcinoma: An integrated review*. *35*(2), 151–

Tan, n, L., Zhou, J., & Luo, G. (2021). Procalcitonin kinetics early after severe alue in diagnosis of sepsis. *Burns*, *47*(8), 1802–1809.

Tesa , & Mendoza-Tesarik, R. (2021). Ovarian Aging: Molecular Mechanisms ement. *Int. J. Mol. Sci.*

Ticinesi, A., Lauretani, F., Nouvenne, A., Porro, E., Fanelli, G., Maggio, M., & Meschi, T. (2017). C-reactive protein (CRP) measurement in geriatric patients hospitalized for acute infection. *European Journal of Internal Medicine*, *37*, 7–12. https://doi.org/10.1016/j.ejim.2016.08.026

Trimboli, P., & Giovanella, L. (2018). Procalcitonin as marker of recurrent medullary thyroid carcinoma: A systematic review and meta-analysis. *Endocrinology and Metabolism*, *33*(2), 204–210.

Troisi, R., Bjørge, T., Gissler, M., Grotmol, T., Kitahara, C. M., Myrtveit Saether, S., Ording, A. G., Sköld, C., Sørensen, H. T., & Trabert, B. (2018). The role of pregnancy, perinatal factors and hormones in maternal Carcinoma risk: A review of the evidence. *Journal of Internal Medicine*, *283*(5), 430–445.

Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., Li, X., Xiong, W., Li, G., Zeng, Z., & Guo, C. (2017). Role of tumor microenvironment in tumorigenesis. *Journal of Carcinoma*, *8*(5), 761–773. https://doi.org/10.7150/jca.17648

Wang, Y., Zhang, Z., Wang, J., & Zhang, X. (2020). Association between C-reactive protein level and subsequent risk of ovarian Carcinoma: A meta-analysis of 13 cohorts in 1,852 ovarian Carcinoma patients. *Medicine*, *99*(5), e18821. https://doi.org/10.1097/MD.0000000000018821

Weiderpass, E., Hashim, D., & Labrèche, F. (2020). Malignant tumors of the female reproductive system. *Occupational Carcinomas*, 439–453.

Whelan, E., Kalliala, I., Semertzidou, A., Raglan, O., Bowden, S., Kechagias, K., Markozannes, G., Cividini, S., McNeish, I., & Marchesi, J. (2022). Risk factors for ovarian Carcinoma: An umbrella review of the literature. *Carcinomas*, *14*(11), 2708.

Whitwell, H. J., Worthington, J., Blyuss, O., Gentry-Maharaj, A., Ryan, A., Gunu, R., Kalsi, J., Menon, U., Jacobs, I., & Zaikin, A. (2020). Improved early detection of ovarian Carcinoma using longitudinal multimarker models. *British Journal of Carcinoma*, *122*(6), 847–856.

Ye, Y., Dai, Q., & Qi, H. (2021). A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian Carcinoma. *Cell Death Discovery*, *7*(1), 1–11.

Zeng, F., Wei, H., Yeoh, E., Zhang, Z., Ren, Z.-F., Colditz, G. A., Tworoger, S. S., & Su, X. (2016). Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Carcinoma: A Meta-analysis of Prospective Studies. *Carcinoma Epidemiology, Biomarkers & Prevention*, *25*(8), 1231–1239. https://doi.org/10.1158/1055-9965.EPI-16-0120

Zheng, G., Yu, H., Kanerva, A., Försti, A., Sundquist, K., & Hemminki, K. (2018). Familial risks of ovarian Carcinoma by age at diagnosis, proband type and histology. *PLOS ONE*, *13*(10), e0205000. https://doi.org/10.1371/journal.pone.0205000

Zhu, M., Ma, Z., Zhang, X., Hang, D., Yin, R., Feng, J., Xu, L., & Shen, H. (2022). C-reactive protein and ian-Carcinoma study of prospective cohort and Mendelian randomization *cine*, *20*(1), 301. https://doi.org/10.1186/s12916-022-02506-x

LAMPIRAN

Lampiran 1

NASKAH PENJELASAN UNTUK RESPONDEN

Assalamualaikum wr.wb. Salam ibu, saya dr. Angga Dewi Umar Wahyu, yang akan melakukan penelitian tentang "PERAN KADAR PROKALSITONIN DAN *C-REACTIVE PROTEIN* SEBAGAI PREDIKTOR KARSINOMA OVARIUM". Karena itu kami sangat mengharapkan ibu bersedia untuk ikut dalam penelitian ini secara sukarela dan mengizinkan kami menggunakan data ibu dalam laporan tertulis maupun laporan secara lisan. Bila ibu bersedia kami mengharapkan ibu memberikan persetujuan secara tertulis. Keikutsertaan ibu dalam penelitian ini bersifat sukarela tanpa paksaan, oleh karena itu ibu berhak untuk menolak atau mengundurkan diri tanpa risiko kehilangan hak untuk mendapatkan pelayanan kesehatan.

Kalau ibu setuju untuk berpartisipasi, kami akan menanyakan beberapa hal antara lain data pribadi ibu dan beberapa pertanyaan terkait keluhan penyakit ibu. Kami menjamin keamanan dan kerahasiaan semua data pada penelitian ini. Data akan disimpan dengan baik dan aman, sehingga hanya bisa dilihat oleh yang berkepentingan saja. Demikian juga pada penyajian baik tertulis maupun pada laporan lisan, data pribadi ibu tetap akan kami rahasiakan. Data penelitian ini akan disajikan pada:

- Program Pendidikan Dokter Spesialis Obstetri dan Ginekologi Fakultas Kedokteran Universitas Hasanuddin (FK UNHAS) Makassar
- Publikasi pada majalah ilmiah dalam dan luar negeri

Bila ibu merasa masih ada hal yang belum jelas atau belum dimengerti dengan baik, maka ibu dapat menanyakan atau minta penjelasan pada saya: dr. Angga Dewi Umar Wahyu

Jika ibu setuju untuk berpartisipasi, diharapkan menandatangani surat persetujuan mengikuti penelitian. Atas kesediaan dan kerja samanya kami ucapkan banyak terima kasih.

Identitas Peneliti

Nama : dr. Angga Dewi Umar Wahyu
Alamat : PPDS Obstetri dan Ginekologi FK UNHAS Makassar
Telepon : 0812-9297-8851

DISETUJUI OLEH KOMISI ETIK
PENELITIAN KESEHATAN
FAK. KEDOKTERAN UNHAS

Makassar, Januari 2023

Lampiran 2

FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN SETELAH MENDAPAT PENJELASAN

Yang bertanda tangan di bawah ini :

Nama :.....

Umur :.....

Alamat :.....

Dengan ini menyatakan bahwa setelah saya mendapatkan penjelasan serta mehamami sepenuhnya maksud dan tujuan penelitian ini.

Saya menyatakan setuju untuk ikut serta dalam penelitian ini. Untuk itu saya bersedia dan tidak keberatan mematuhi semua ketentuan yang berlaku dalam penelitian ini dan memberikan keterangan yang sebenarnya. Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini tanpa kehilangan hak saya untuk mendapat pelayanan kesehatan. Juga saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti. Demikan juga biaya perawatan dan pengobatan bila terjadi hal-hal yang tidak diingikan akibat penelitian ini, akan dibiayai oleh peneliti.

Demikianlah pernyataan ini saya buat dengan penuh kesadaran untuk dapat dipergunakan sebagaimana mestinya.

	NAMA	TANDA TANGAN	Tanggal
Saksi 1	.....	.....	.....
Saksi 2	.....	.....	.....

Penanggung Jawab Penelitian

Nama : dr. Angga Dewi Umar Wahyu

Alamat : Perum Osaka Garden No. 17 Tanjung Bunga

Telepon : 0812-9297-8851

Penanggung Jawab Medis

Nama : Prof. Dr. dr. H. Syahrul Rauf, Sp. OG (K)

Alamat : Jl. Monginsidi Lama No. 22

Telepon : 0811-416-070

Lampiran 3

FORMULIR PENELITIAN – Kuesioner pasien

KADAR PROKALSITONIN DAN *C-REACTIVE PROTEIN* SEBAGAI PREDIKTOR KARSINOMA OVARIUM

I. IDENTITAS

1. Nama : .....
2. Umur : .....
3. Alamat : .....
4. No. HP/ Telpon : .....
5. Pekerjaan : .....
6. Pendidikan terakhir : .....
7. Suku bangsa : .....
8. Status perkwainan :.....
9. Lama Perkawinan : .....
10. Paritas : .....
11. Rumah sakit/ No.RM : .....

II. Klinis pasien sebelum operasi :

1. Keadaan umum
2. Berat badan/ Tinggi badan
3. IMT
4. Tekanan darah
5. Haid terakhir
6. Gangguan haid :
    1) Dismenore
    2) Menoragi
    3) Menometroragia
    4) Metroragia
    5) Menopause
    6) Lain.....'
7. Nafsu makan : 1. Berkurang 2. Tetap
8. Riwayat penyakit : .....
9. Riwayat operasi sebelumnya : .....

asepsi/lamanya :.....

akit Karsinoma ovarium dalam keluarga :.....

erokok : 1. Ya (.....batang/hari) 2. Tidak

III. PEMERIKSAAN LABORATORIUM KLINIK, PATOLOGI ANATOMI DAN RADIOLOGI

Prokalsitonin : .....
CRP : .....
CA- 125 :.....
Hasil pemeriksaan PA :.....
USG :.....
BNO-IVP (Bila ada) :.....
CT- Scan (Bila ada) :.....

Lampiran 4

DUMMY TABEL

Tabel 8 Karakteristik Pasien

Variabel	Mean (SD)	n (%)
Usia		
>50 tahun		
≤50 tahun		
Pekerjaan		
Bekerja		
Tidak bekerja		
Paritas		
Nullipara		
Para		
Jenis Massa		
Kista ovarium		
Karsinoma musinous		
Karsinoma serous		
Karsinoma lainnya		
Karsinoma		
Epitelial		
Non-epitelial		
Status menopause		
Sudah menopause		
Belum menopause		
Kotrasepsi hormonal		
Pakai		
Tidak pakai		
PCT		
CRP		

Tabel 9 Hubungan Kadar PCT berdasarkan Tipe

		Kadar PCT rata-rata	95% IK	*p-value*
Tipe	Karsinoma ovarium			
	n			

Tab **PCT berdasarkan Cut Off tipe**

	Kadar PCT		95% IK	*p-value*
	≥ cut off	< cut off		

Tipe	Karsinoma ovarium			
	Kista ovarium			

Sensitivitas dan spesifitas

Tabel 11 Hubungan Kadar CRP berdasarkan Tipe

		Kadar CRP rata-rata	95% IK	*p-value*
Tipe	Karsinoma ovarium			
	Kista ovarium			

Tabel 12 Hubungan Kadar CRP berdasarkan Cut Off tipe

		Kadar CRP		95% IK	*p-value*
		≥ cut off	< cut off		
Tipe	Karsinoma ovarium				
	Kista ovarium				

Sensitivitas dan spesifitas

LAMPIRAN 5. Rekomendasi Persetujuan Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 550/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 7 Agustus 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23070476	No Sponsor	
Peneliti Utama	**dr. Angga Dewi Umar Wahyu**	Sponsor	
Judul Peneliti	KADAR PROKALSITONIN DAN C-REAKTIF PROTEIN SEBAGAI PREDIKTOR KANKER OVARIUM.		
No Versi Protokol	2	Tanggal Versi	**31 Juli 2023**
No Versi PSP	2	Tanggal Versi	**31 Juli 2023**
Tempat Penelitian	RS Universitas Hasanuddin Dan RSUP Dr. Wahidin Sudirohusodo RS Ibnu Sina Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **7 Agustus 2023** sampai **7 Agustus 2024**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di Implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan

Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap
i resiko rendah
hir setelah Penelitian berakhir
an dari prokol yang disetujui (protocol deviation / violation)
ran yang ditentukan

LAMPIRAN 6
Output SPSS

Kruskal-Wallis Test

Ranks

	status	N	Mean Rank
PCT	Karsinoma ovarium	59	56.59
	non-karsinoma	28	17.46
	Total	87	

Test Statistics[a,b]

	PCT
Chi-Square	45.569
df	1
Asymp. Sig.	.000

a. Kruskal Wallis Test
b. Grouping Variable: status

Group Statistics

	status	N	Mean	Std. Deviation	Std. Error Mean
PCT	Karsinoma ovarium	59	.8524	.51963	.06765
	non-karsinoma	28	.0812	.17400	.03288
CRP	Karsinoma ovarium	59	1.5064	.33009	.04297
	non-karsinoma	28	1.5547	.38796	.07332

Mann-Whitney Test

Ranks

	status	N	Mean Rank	Sum of Ranks
CRP	Karsinoma ovarium	59	41.78	2465.00
	non-karsinoma	28	48.68	1363.00
	Total	87		

Test Statistics[a]

	CRP
	695.000
	2465.000
	-1.190
	.234

tatus

umur_kategorik * status

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	7.965[a]	1	.005		
Continuity Correction[b]	6.627	1	.010		
Likelihood Ratio	8.975	1	.003		
Fisher's Exact Test				.006	.004
Linear-by-Linear Association	7.874	1	.005		
N of Valid Cases	87				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 8,69.
b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval Lower	Upper
Odds Ratio for umur_kategorik (>50 / <50)	5.714	1.549	21.080
For cohort status = Karsinoma ovarium	1.524	1.184	1.961
For cohort status = non-karsinoma	.267	.088	.808
N of Valid Cases	87		

pekerjaan * status

Crosstab

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.242[a]	1	.623		
Continuity Correction[b]	.046	1	.831		
Likelihood	.238	1	.626		
Fisher's Ex				.782	.409
Linear-by-L	.239	1	.625		
N of Valid	87				

a. 0 cells (, ess than 5. The minimum expected count is 6,11.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval Lower	Upper
Odds Ratio for pekerjaan (bekerja / tidak bekerja)	.766	.264	2.221
For cohort status = Karsinoma ovarium	.914	.626	1.334
For cohort status = non-karsinoma	1.193	.600	2.373
N of Valid Cases	87		

paritas * status

Crosstab

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.097[a]	1	.756		
Continuity Correction[b]	.003	1	.959		
Likelihood Ratio	.096	1	.757		
Fisher's Exact Test				.798	.474
Linear-by-Linear Association	.096	1	.757		
N of Valid Cases	87				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 7,40.
b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval Lower	Upper
Odds Ratio for paritas (nullipara / para)	.852	.311	2.335
Karsinoma	.949	.674	1.334
= non-	1.113	.571	2.169
	87		

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
cut_off_pct * status	78	81.3%	18	18.8%	96	100.0%

cut_off_pct * status Crosstabulation

			status		
			Karsinoma ovarium	non-karsinoma	Total
cut_off_pct	>0.33	Count	42	3	45
		% within cut_off_pct	93.3%	6.7%	100.0%
	<0.33	Count	17	16	33
		% within cut_off_pct	51.5%	48.5%	100.0%
Total		Count	59	19	78
		% within cut_off_pct	75.6%	24.4%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	18.069[a]	1	.000		
Continuity Correction[b]	15.871	1	.000		
Likelihood Ratio	18.847	1	.000		
Fisher's Exact Test				.000	.000
Linear-by-Linear Association	17.838	1	.000		
N of Valid Cases	78				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 8,04.
b. Computed only for a 2x2 table

Risk Estimate

		95% Confidence Interval	
	Value	Lower	Upper
Odds Ratio for cut_off_pct (>0.33 / <0.33)	13.176	3.396	51.119
For cohort status = Karsinoma ovarium	1.812	1.289	2.546
= non-	.138	.044	.434
	78		

Crosstabs

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
cut_off_pct * status	87	100.0%	0	0.0%	87	100.0%

cut_off_pct * status Crosstabulation

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	43.713[a]	1	.000		
Continuity Correction[b]	40.658	1	.000		
Likelihood Ratio	46.959	1	.000		
Fisher's Exact Test				.000	.000
Linear-by-Linear Association	43.210	1	.000		
N of Valid Cases	87				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 10,94.
b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for cut_off_pct (>0.33 / <0.33)	46.296	11.508	186.254
For cohort status = Karsinoma ovarium	3.564	2.027	6.265
For cohort status = non-karsinoma	.077	.025	.235
N of Valid Cases	87		

Crosstabs

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
kontral	87	100.0%	0	0.0%	87	100.0%
menop	87	100.0%	0	0.0%	87	100.0%

kontrahormo * status

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	2.696[a]	1	.101		
Continuity Correction[b]	1.943	1	.163		
Likelihood Ratio	2.629	1	.105		
Fisher's Exact Test				.137	.083
Linear-by-Linear Association	2.665	1	.103		
N of Valid Cases	87				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 8,69.
b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval Lower	Upper
Odds Ratio for kontrahormo (pakai / tidak pakai)	.455	.176	1.176
For cohort status = Karsinoma ovarium	.758	.523	1.097
For cohort status = non-karsinoma	1.667	.919	3.021
N of Valid Cases	87		

menopaususe * status

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	7.455[a]	1	.006		
Continuity Correction[b]	6.195	1	.013		
Likelihood Ratio	8.163	1	.004		
Fisher's Exact Test				.008	.005
Linear-by-Linear Association	7.369	1	.007		
N of Valid	87				

a. 0 cells (ess than 5. The minimum expected count is 9,66.
b. Comput

Risk Estimate

	Value	95% Confidence Interval Lower	Upper
Odds Ratio for menopaususe (Belum Menopause / Sudah Menopause)	.212	.065	.686
For cohort status = Karsinoma ovarium	.668	.514	.868
For cohort status = non-karsinoma	3.158	1.207	8.262
N of Valid Cases	87		

Crosstabs

Case Processing Summary

	Cases Valid N	Valid Percent	Missing N	Missing Percent	Total N	Total Percent
menopause * status	87	100.0%	0	0.0%	87	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	7.455[a]	1	.006		
Continuity Correction[b]	6.195	1	.013		
Likelihood Ratio	8.163	1	.004		
Fisher's Exact Test				.008	.005
Linear-by-Linear Association	7.369	1	.007		
N of Valid Cases	87				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 9,66.
b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval Lower	Upper
enopause ause)	4.727	1.457	15.333
Karsinoma	1.497	1.152	1.946
= non-	.317	.121	.828
	87		

ROC Curve

Notes

Output Created		27-MAY-2024 16:02:41
Comments		
Input	Data	C:\Users\Downloads\data angga.sav
	Active Dataset	DataSet1
	Filter	<none>
	Weight	<none>
	Split File	<none>
	N of Rows in Working Data File	87
Missing Value Handling	Definition of Missing	User-defined missing values are treated as missing.
	Cases Used	Statistics are based on all cases with valid data for all variables in the analysis.
Syntax		ROC PCT BY status (1) /PLOT=CURVE(REFERENCE) /PRINT=SE COORDINATES /CRITERIA=CUTOFF(INCLUDE) TESTPOS(LARGE) DISTRIBUTION(FREE) CI(95) /MISSING=EXCLUDE.
Resources	Processor Time	00:00:00,44
	Elapsed Time	00:00:00,53

```
[DataSet1] C:\Users\Downloads\data angga.sav
```

Case Processing Summary

status	Valid N (listwise)
Positive[a]	59
Negative	28

test result
stronger
tive actual

al state is

Area Under the Curve

Test Result Variable(s): PCT

Area	Std. Error[a]	Asymptotic Sig.[b]	Asymptotic 95% Confidence Interval	
			Lower Bound	Upper Bound
.950	.024	.000	.903	.996

a. Under the nonparametric assumption

b. Null hypothesis: true area = 0.5

	Positive if Greater Than or Equal To[a]	Sensitivity	Spesivity
1	-0,9999	1,000	0,000
2	0,0006	1,000	0,036



3	0,0012	1,000	0,071
4	0,0014	1,000	0,107
5	0,0019	1,000	0,143
6	0,0024	0,983	0,143
7	0,0029	0,983	0,179
8	0,0039	0,983	0,214
9	0,0055	0,983	0,250
10	0,0073	0,983	0,286
11	0,0085	0,983	0,357
12	0,0104	0,983	0,393
13	0,0127	0,983	0,429
14	0,0134	0,983	0,464
15	0,0141	0,983	0,500
16	0,0169	0,983	0,536
17	0,0197	0,983	0,571
18	0,0205	0,983	0,607
19	0,0241	0,983	0,643
20	0,0274	0,983	0,679
21	0,0340	0,966	0,679
22	0,0415	0,966	0,714
23	0,0433	0,966	0,750
24	0,0590	0,966	0,786
25	0,0758	0,966	0,821
26	0,0825	0,966	0,857
27	0,0973	0,949	0,857
28	0,1156	0,949	0,893
29	0,1403	0,932	0,893
30	0,1572	0,915	0,893
31	0,1628	0,898	0,893
32	0,1962	0,881	0,893
33	0,2328	0,864	0,893
34	0,2451	0,847	0,893
35	0,2603	0,831	0,893
	)88	0,814	0,893
	)43	0,797	0,893
	)76	0,780	0,893
	)52	0,763	0,893
	)84	0,746	0,893

41	0,5046	0,729	0,893
42	0,5220	0,729	0,929
43	0,5342	0,712	0,929
44	0,5371	0,695	0,929
45	0,5588	0,678	0,929
46	0,5815	0,678	0,964
47	0,5996	0,661	0,964
48	0,6171	0,661	1,000
49	0,6384	0,644	1,000
50	0,6752	0,627	1,000
51	0,6963	0,610	1,000
52	0,7098	0,593	1,000
53	0,7239	0,576	1,000
54	0,7400	0,559	1,000
55	0,7549	0,542	1,000
56	0,7576	0,525	1,000
57	0,7758	0,508	1,000
58	0,8059	0,492	1,000
59	0,8313	0,475	1,000
60	0,8589	0,458	1,000
61	0,8746	0,441	1,000
62	0,8826	0,424	1,000
63	0,9182	0,407	1,000
64	0,9488	0,390	1,000
65	0,9727	0,373	1,000
66	1,0165	0,356	1,000
67	1,0555	0,339	1,000
68	1,0765	0,322	1,000
69	1,0875	0,305	1,000
70	1,1008	0,288	1,000
71	1,1378	0,271	1,000
72	1,1785	0,254	1,000
73	1,2504	0,237	1,000
	63	0,220	1,000
	04	0,203	1,000
	06	0,186	1,000
	03	0,169	1,000
	11	0,153	1,000

79	1,5064	0,136	1,000
80	1,5440	0,119	1,000
81	1,6334	0,102	1,000
82	1,7297	0,085	1,000
83	1,7723	0,068	1,000
84	1,7884	0,051	1,000
85	1,8198	0,034	1,000
86	1,8955	0,017	1,000
87	2,9539	0,000	1,000

Statistics

Variable	Staging	N	Mean	StDev	Minimum	Q1	Median	Q3	Maximum
Kadar Prokalsitonin	IA	6	0,976533	0,655184	0,0022	0,37375	1,0394	1,57525	1,7704
	IC1	5	0,74812	0,400222	0,1577	0,34585	0,8739	1,0875	1,0942
	IC3	7	1,03393	0,640493	0,0874	0,5344	0,9511	1,689	1,7742
	IIB	2	1,29685	0,763887	0,7567	0,7567	1,29685	1,837	1,837
	IIIA2	3	0,836767	0,856856	0,1679	0,1679	0,5398	1,8026	1,8026
	IIIB	6	0,98695	0,467041	0,3425	0,605975	0,9633	1,4302	1,5778
	IIIC	20	0,776445	0,545752	0,0276	0,254625	0,8313	1,26077	1,9539
	IVB	10	0,6902	0,197382	0,2245	0,61145	0,72385	0,813575	0,9464

Statistics

Variable	Grading	N	Mean	StDev	Minimum	Q1	Median	Q3	Maximum
Kadar Prokalsitonin	high grade	33	0,783670	0,471450	0,0276	0,3343	0,7567	1,13775	1,8026
		26	0,939723	0,572520	0,0022	0,525275	0,8826	1,3661	1,9539

		N	Mean	StDev	Minimum	Q1	Median	Q3	Maximum

Kadar Prokalsitonin	tidak	30	1,01623	0,544700	0,0022	0,6577	1,0165	1,5045	1,9539
	ya	29	0,683	0,439945	0,0276	0,2988	0,6566	0,91085	1,8026

Statistics

Variable	Histologi	N	Mean	StDev	Minimum	Q1	Median	Q3	Maximum
Kadar Prokalsitonin	clear cell	3	1,18803	0,851031	0,2245	0,2245	1,5026	1,837	1,837
	endometrioid	3	0,7371	0,514222	0,1679	0,1679	0,8753	1,1681	1,1681
	germ cell	1	0,1566	*	0,1566	0,1566	0,1566	0,1566	0,1566
	granulosa cell	1	0,8899	*	0,8899	0,8899	0,8899	0,8899	0,8899
	mucinous	22	0,902036	0,600097	0,0022	0,5249	0,7427	1,4127	1,9539
	serous	29	0,814731	0,429392	0,0276	0,4459	0,793	1,1008	1,5778

Statistics

Variable	Histopatologi	N	Mean	StDev	Minimum	Q1	Median	Q3	Maximum
Kadar Prokalsitonin	epitelial	57	0,863989	0,520438	0,0022	0,49835	0,793	1,2504	1,9539
	non epitelial	2	0,52325	0,518521	0,1566	0,1566	0,52325	0,8899	0,8899

LAMPIRAN 7